Category

Published on

30 Mar 2009

Abstract

This presentation examines a claim made by PhRMA on behalf of pharmaceutical manufacturing companies of America, and the response of the International Committee of Medical Journal Editors (ICMJE) questioning drug company publication policies and practices. Also considered are changes in law (2007) governing Food and Drug Administration regulation and public access to results of clinical trials. I propose that the contractual relation between the investigator and subjects (patients) is the source of a competing claim requiring public access to the evidence of clinical trials. The ownership claim is not settled. Do not individuals acting on their own best judgment and publishing data for the public good contrary to corporate authority deserve the support of their institutions and professional associations?

Bio

Sam Richmond is Professor Emeritus, Department of Philosophy, Cleveland State University. He served as Director or Co-director of the Bioethics Program at CSU from 1998-2008. His research interests include simplicity and science, simplicity and rational change of mind, and administrative discretion in relation to mandate of lawful corporate authority.

Credits

Research for this presentation was supported in part by a Presidential Initiative Grant, Cleveland State University.

Get Involved

Legal

nanoHUB.org, a resource for nanoscience and nanotechnology, is supported by the National Science Foundation and other funding agencies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.